Real World Data of Clinical Trial Eligibility and Outcome Analysis in Patients With Metastatic NSCLC

被引：0

作者：

Yellala, A. ^{[1
]}

Tulpule, S. ^{[2
]}

Oakley, C. ^{[1
]}

High, R. ^{[1
]}

Ganti, A. K. ^{[1
]}

Marr, A. ^{[1
]}

机构：

[1] Univ Nebraksa, Med Ctr, Hematol Oncol, Omaha, NE USA

[2] St Louis Univ, Sch Med, St Louis, AL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P10.01

引用

页码：S998 / S998

页数：1

共 50 条

[21] Long-term outcome estimation combining real world with clinical trial data in metastatic melanoma following a Bayesian approach
Castro, Y.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 65 - 66
[22] Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real World Population of Advanced Lung Cancer Patients?
Al-Baimani, Khalid
Jonker, Hannah
Zhang, Tinghua
Goss, Glenwood
Laurie, Scott A.
Nicholas, Garth
Wheatley-Price, Paul
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S368 - S369
[23] Generalizability of common cancer clinical trial eligibility criteria in the real world.
Karim, Safiya
Xu, Yuan
Quan, May Lynn
Dort, Joseph C.
Bouchard-Fortier, Antoine
Cheung, Winson Y.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial
Buzzatti, G.
Allorant, A.
Verlingue, L.
Brandao, D.
Massard, C.
Hollebecque, A.
Ferte, C.
Lacroix, L.
Ngo-Camus, M.
Auger, N.
Scoazec, J.
Ammari, S.
Gazzah, A.
Planchard, D.
Besse, B.
Solary, E.
Andre, F.
Michiels, S.
Soria, J.
Menis, J.
ANNALS OF ONCOLOGY, 2017, 28
[25] Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC
Doebele, Robert C.
Perez, Laura
Trinh, Huong
Martinec, Michael
Martina, Reynaldo
Riehl, Todd
Krebs, Matthew G.
Meropol, Neal J.
Wong, William B.
Crane, Gracy
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1271 - 1282
[26] Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data
Stelljes, Matthias
Sockel, Katja
Floeth, Matthias
Schetelig, Johannes
Bornhauser, Martin
Reicherts, Christian
Lenz, Georg
Schroeder, Thomas
Markiewicz, Miroslaw
Labussiere-Wallet, Helene
Remenyi, Peter
Ciceri, Fabio
Khan, Imran
Pichlmeier, Uwe
Li, Xieran
Stolzel, Friedrich
BONE MARROW TRANSPLANTATION, 2025, 60 (01) : 103 - 106
[27] Ethnic disparities in biomarker testing of patients with metastatic NSCLC in the United States: A real-world analysis
Jayram, Diya
Bellur, Shreyas S.
Ozair, Ahmad
Ahmad, Shahzaib
Ganiyani, Mohammad Arfat
Khosla, Atulya Aman
McCracken, Andrea
Marada, Suresh
Hurmiz, Charlie
Bowman, Steven, II
Ahluwalia, Manmeet Singh
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Impact of broadening clinical trial eligibility criteria for advanced non small cell lung cancer patients: Real-world analysis.
Harvey, R. Donald
Rubinstein, Wendy S.
Ison, Gwynn
Khozin, Sean
Chen, Li
Miller, Robert S.
Jun, Monika
Stepanski, Edward
Hyde, Brigham
Uldrick, Thomas S.
Komatsoulis, George Anthony
Roberts, Jeremy
Garrett-Mayer, Elizabeth
Schilsky, Richard L.
Schenkel, Caroline
Kim, Edward S.
Bruinooge, Suanna S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[29] "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey
Padovani, Alessandro
Caratozzolo, Salvatore
Rozzini, Luca
Pilotto, Andrea
Benussi, Alberto
Tedeschi, Gioacchino
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (02) : 626 - 628
[30] Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients
Niels Reinmuth
Nadine Payer
Thomas Muley
Hans Hoffmann
Felix JF Herth
Matthias Villalobos
Michael Thomas
Respiratory Research, 14

← 1 2 3 4 5 →